Fig. 3.

Proportion of patients with a clinical response to LDX or ATX treatment (defined as a CGI-I score of 1 or 2) at each weekly study visit using LOCF. Values are shown as the proportion of responders ±95 % confidence intervals based on LOCF. ***p < 0.001, **p < 0.01 based on a Cochran–Mantel–Haenszel test stratified by country comparing LDX treatment with ATX. ATX atomoxetine, CGI-I Clinical Global Impressions-Improvement, LDX lisdexamfetamine dimesylate, LOCF last-observation-carried-forward